NewsMV
The catalyst in focus for TNGX: Tango Therapeutics, Inc. confirmed in an August 6 SEC filing that Dr.
Barbara Weber's employment as Executive Chair ended August 3, 2026, simultaneously triggering her resignation from all officer roles and from the company's board of directors.
The separation arrived under the terms of her Amended and Restated Employment Agreement, dated January 8, 2026.
What to watch: the execution of a Separation Agreement that, once signed and not revoked, releases the full package of severance benefits the company has offered.
Keep reading